Nishadil
Ads Astrology Calendar Devs Domains Finance Pay Rewards Weather
Signup Signin
Washington | 15°C (overcast clouds)
Topic Feed

ObesityDrugs

Showing the latest stories and updates for this topic.
Pharmalot's Pulse Check: Navigating Pharma's Twists and Turns

Pharmalot's Pulse Check: Navigating Pharma's Twists and Turns
The Shifting Sands of Pharma: Innovation, Access, and Lingering Questions in Early 2026

The Shifting Sands of Pharma: Innovation, Access, and Lingering Questions in Early 2026
Structure Therapeutics CEO Charts Course for Next-Gen Obesity Treatments

Structure Therapeutics CEO Charts Course for Next-Gen Obesity Treatments
Dr. Joel Habener, Visionary Pioneer of Diabetes Treatment and GLP-1 Research, Dies at 88

Dr. Joel Habener, Visionary Pioneer of Diabetes Treatment and GLP-1 Research, Dies at 88
The Great Pharma Race: GLP-1s, Billions, and the Battle for What's Next

The Great Pharma Race: GLP-1s, Billions, and the Battle for What's Next
The Curious Case of Microdosing Obesity Drugs: A New Trend or a Risky Gamble?

The Curious Case of Microdosing Obesity Drugs: A New Trend or a Risky Gamble?
Eli Lilly's Trillion-Dollar Triumph: Reshaping the Pharma Landscape

Eli Lilly's Trillion-Dollar Triumph: Reshaping the Pharma Landscape
The Trillion-Dollar Bet: How Eli Lilly is Reshaping the Global Economy

The Trillion-Dollar Bet: How Eli Lilly is Reshaping the Global Economy
The Pharma Giants' Bold Leap: Novo Nordisk and Eli Lilly Eyeing Direct Sales of Obesity Drugs to Employers

The Pharma Giants' Bold Leap: Novo Nordisk and Eli Lilly Eyeing Direct Sales of Obesity Drugs to Employers
The Great Weight Race: Can New Contenders Navigate the Treacherous Path of Next-Gen Obesity Drugs?

The Great Weight Race: Can New Contenders Navigate the Treacherous Path of Next-Gen Obesity Drugs?
The Great Indian Weight Loss Gambit: A New Oral Frontier Arrives

The Great Indian Weight Loss Gambit: A New Oral Frontier Arrives
The Great Pharmaceutical Scramble: Pfizer Bags Metsea in High-Stakes Obesity Drug Duel

The Great Pharmaceutical Scramble: Pfizer Bags Metsea in High-Stakes Obesity Drug Duel
The Prize Fight for Progress: Pfizer Snags Metacrine in a High-Stakes Metabolic Drug Scramble

The Prize Fight for Progress: Pfizer Snags Metacrine in a High-Stakes Metabolic Drug Scramble
The Great GLP-1 Gold Rush: Pfizer Jumps into the Billion-Dollar Battle for Weight Loss Dominance

The Great GLP-1 Gold Rush: Pfizer Jumps into the Billion-Dollar Battle for Weight Loss Dominance
The High-Stakes Game of Weight Loss: Pfizer's Gambit in the GLP-1 Gold Rush

The High-Stakes Game of Weight Loss: Pfizer's Gambit in the GLP-1 Gold Rush
The Great Weight Debate: Unpacking the White House's Bold Move on Obesity Drugs

The Great Weight Debate: Unpacking the White House's Bold Move on Obesity Drugs
A Grand Bargain for Health? The Looming Question of Obesity Drugs and Who Pays.

A Grand Bargain for Health? The Looming Question of Obesity Drugs and Who Pays.
The Watchdogs Are Barking: Why Metsera's Big Deal Just Hit a Snag

The Watchdogs Are Barking: Why Metsera's Big Deal Just Hit a Snag
The Billion-Dollar Beatdown: How Novo Nordisk Clinched Metsera in a High-Stakes Pharma Showdown

The Billion-Dollar Beatdown: How Novo Nordisk Clinched Metsera in a High-Stakes Pharma Showdown
The Great Negotiation: Big Pharma, Weight Loss, and the White House

The Great Negotiation: Big Pharma, Weight Loss, and the White House
The Weight of Expectation: FDA, Obesity Drugs, and the Uneasy Dance Between Speed and Safety

The Weight of Expectation: FDA, Obesity Drugs, and the Uneasy Dance Between Speed and Safety
The Billion-Dollar Standoff: Pfizer Takes On Novo Nordisk for a Slice of the Future

The Billion-Dollar Standoff: Pfizer Takes On Novo Nordisk for a Slice of the Future
The Weight-Loss Gold Rush: Why All Eyes Are On Viking Therapeutics After a Hefty Biotech Deal

The Weight-Loss Gold Rush: Why All Eyes Are On Viking Therapeutics After a Hefty Biotech Deal
The Great Weigh-In: Pharma's Fierce Battle for the Future of Obesity, and What Else Keeps Them Up at Night

The Great Weigh-In: Pharma's Fierce Battle for the Future of Obesity, and What Else Keeps Them Up at Night
The Pharmaceutical Whirlwind: From Weight Loss Wonders to Mind-Altering Medicines, A New Era Unfolds

The Pharmaceutical Whirlwind: From Weight Loss Wonders to Mind-Altering Medicines, A New Era Unfolds
A Major Turnaround: US Obesity Rates Witness Significant Decline in 2024

A Major Turnaround: US Obesity Rates Witness Significant Decline in 2024
A Healthier Horizon: United States Witnesses Encouraging Decline in Obesity Rates for 2024

A Healthier Horizon: United States Witnesses Encouraging Decline in Obesity Rates for 2024
A Healthier Horizon: US Obesity Rates Show Promising Decline in 2024

A Healthier Horizon: US Obesity Rates Show Promising Decline in 2024
Pfizer's Bold Gambit: Unleashing New Weapons in the Global Battle Against Obesity

Pfizer's Bold Gambit: Unleashing New Weapons in the Global Battle Against Obesity
The GLP-1 Revolution: Why the Market's Reaction to Novo Nordisk and Eli Lilly is Lagging

The GLP-1 Revolution: Why the Market's Reaction to Novo Nordisk and Eli Lilly is Lagging
The Weighty Truth: Are Next-Gen Obesity Drugs Worth Their Premium Price Tag?

The Weighty Truth: Are Next-Gen Obesity Drugs Worth Their Premium Price Tag?
Load more..